Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 142 Endometrial Neoplasms 85 Uterine Cervical Neoplasms 71 Breast Neoplasms 42 Fallopian Tube Neoplasms 38 Colorectal Neoplasms 34 Carcinoma, Non-Small-Cell Lung 32 Pancreatic Neoplasms 24 Neoplasms 23 Prostatic Neoplasms 22 Neoplasm Metastasis 21 Stomach Neoplasms 19 Triple Negative Breast Neoplasms 18 Urinary Bladder Neoplasms 17 Esophageal Neoplasms 17 Melanoma 16 Squamous Cell Carcinoma of Head and Neck 15 Lung Neoplasms 15 Carcinoma, Renal Cell 15 Carcinoma, Ovarian Epithelial 15 Head and Neck Neoplasms 14 Sarcoma 13 Carcinoma, Hepatocellular 13 Uterine Neoplasms 11 Colonic Neoplasms 11 Cholangiocarcinoma 11 Carcinoma, Transitional Cell 11 Rectal Neoplasms 10 Vulvar Neoplasms 9 Small Cell Lung Carcinoma 9

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Gynecologic × 30 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡